Catalyst Brief

← Calendar

Readoutin 14d

AskGene Pharma, Inc. — ASKB589

Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibitor in advanced or metastatic GC/GEJ adenocarcinoma.

Date
Dec 2026
Type
Readout
Indication
GC/GEJ Adenocarcinoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.